Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference.
Piper Sandler 33rd Virtual Annual Healthcare Conference
Date: Tuesday, November 30 through Thursday, December 2, 2021
Vor’s pre-recorded presentation will be available on-demand from Piper Sandler beginning on Monday, November 22nd at 10:00 am ET and can also be accessed via the Investors section of the Company's website at www.vorbio.com.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Vice President, Corporate Communications, Vor
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.33 |
| Daily Change: | -0.03 -2.21 |
| Daily Volume: | 359,472 |
| Market Cap: | US$165.640M |
January 08, 2025 December 27, 2024 September 05, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
